Global Subcutaneous Immunoglobulin (SCIG) Market Projected to Grow at 12.7% CAGR, Reaching $23.23 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Subcutaneous Immunoglobulin (SCIG) Industry Market Size Be by 2025?
The market for subcutaneous immunoglobulin (SCIG) has seen a swift expansion in the recent past. The market size is projected to escalate from $12.72 billion in 2024 to $14.39 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.1%. Factors contributing to this historical growth include a higher occurrence of immunodeficiency disorders, an increase in patient inclination towards home-based care, improved therapeutic efficacy, and elevated awareness and diagnosis rates. Additionally, favourable reimbursement policies have also fostered market growth.

What's the Long-Term Growth Forecast for the Subcutaneous Immunoglobulin (SCIG) Market Size Through 2029?
In the coming years, the subcutaneous immunoglobulin (SCIG) market is projected to experience considerable growth, reaching a value of "$23.23 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. This expected growth over the forecast period is attributed to factors such as the increasing incidence of neurological conditions, heightened prevalence of autoimmune diseases, growing acceptance and awareness of immunoglobulin treatments, as well as their expanding use in dermatology and neurology, and broadening healthcare facilities. Key trends anticipated over this forecast period include advancements in medication delivery systems, rising demand for home-based infusion therapies, progress in the field of antibody therapy, and innovations in SCIG formulations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

What Are the Key Growth Drivers Fueling the Subcutaneous Immunoglobulin (SCIG) Market Expansion?
The surge in secondary immunodeficiency diseases is anticipated to fuel the expansion of the subcutaneous immunoglobulin market in the future. Secondary immunodeficiency diseases, which are the result of factors other than the immune system weakening or impairing the immune system, are increasing due to elements such as aging populations, the application of immunosuppressive therapies, and environmental toxins. Subcutaneous immunoglobulin therapy gives antibodies which can reinforce a fragile immune system, primarily in long-term illnesses like HIV or autoimmune diseases. It helps in preventing infections and sustaining immunological function throughout therapy. For example, the UK Health Security Agency, a UK-based governmental agency, reported in October 2023 that there were 3,805 new HIV diagnoses in England in 2022. This represented a 22% increase from the prior year. Consequently, the rise in secondary immunodeficiency diseases is propelling the subcutaneous immunoglobulin market's expansion.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

What Trends Will Shape the Subcutaneous Immunoglobulin (SCIG) Market Through 2029 and Beyond?
The subcutaneous immunoglobulin market is being driven by primary players who are innovating with subcutaneous human-klhw, a distinctive mixture containing human immune globulins (Ig) that boost the immune system. This formulation, designed for subcutaneous application, is being used to treat primary immunodeficiency diseases in humans. For example, in March 2022, Grifols S.A., a pharmaceutical company based in Spain, introduced XEMBIFY 20% subcutaneous immunoglobulin (SCIG), intentionally created to help those with primary immunodeficiency, addressing a critical health need for individuals with compromised immune systems. XEMBIFY, a pre-prepared formulation, streamlines the treatment process and enhances patient comfort. Its stability at room temperature lasting for up to 24 months eliminates the need for cold storage during transport, offering significant advantages in various healthcare environmental conditions.

How Is the Subcutaneous Immunoglobulin (SCIG) Market Segmented?
The subcutaneous immunoglobulin (scig) market covered in this report is segmented -

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp

Which Companies Are Leading the Charge in Subcutaneous Immunoglobulin (SCIG) Market Innovation?
Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy's Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc

Which Regions Are Leading the Global Subcutaneous Immunoglobulin (SCIG) Market in Revenue?
North America was the largest region in the subcutaneous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.